Use of MEK1 inhibitors as protective agents against damage due to ischemia
AssigneeThe General Hospital Corporation
InventorsAlessandro Alessandrini, Joseph Bonventre, Michael A. Moskowitz, Shobu Namura
Life of this patent
Estimating the term…
Abstract
The invention relates to the use of MEK1 inhibitors to reduce tissue damage resulting from ischemia and/or reperfusion, particularly brain damage associated with ischemia resulting from stroke. Pharmaceutical compositions, kits and perfusion fluids including MEK1 inhibitors are also provided.
Claims14
A pharmaceutical composition comprising
- a MEK1 inhibitor, and
- a non-MEK1 inhibitor anti-stroke agent selected from the group consisting of N-methyl-D-aspartate (NMDA) receptor antagonists, immunosuppressants and caspase inhibitors, together in an amount effective for treating an ischemic condition.
A method for treating a subject having a condition characterized by ischemia comprising
- administering to a subject in need of such treatment a MEK1 inhibitor in an amount effective to reduce MEK1 activity, wherein the subject is free of symptoms otherwise calling for treatment with the MEK1 inhibitor, and wherein the MEK1 inhibitor is a (phenylthio)butadiene compound.
A method for treating a subject having a condition characterized by hypoxia comprising
- administering to a subject in need of such treatment a MEK1 inhibitor in an amount effective to reduce MEK1 activity, wherein the subject is free of symptoms otherwise calling for treatment with the MEK1 inhibitor.
A method for treating a subject having a condition characterized by glutamate toxicity comprising
- administering to a subject in need of such treatment a MEK1 inhibitor in an amount effective to reduce MEK1 activity, wherein the subject is free of symptoms otherwise calling for treatment with the MEK1 inhibitor.
Dependencies are inferred from the claim text.